Zymeworks (ZYME) Income from Continuing Operations (2021 - 2026)
Zymeworks (ZYME) reported Income from Continuing Operations of 44162000.0 for Q1 2026, down 95.1% on a YoY basis from 900586515.32 in Q1 2025, and down 7.17% sequentially from 41209000.0 in Q4 2025.
Zymeworks (ZYME) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Income from Continuing Operations data on file, last reported at 44162000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 95.1% year-over-year to 44162000.0; the trailing twelve-month figure through Mar 2026 stood at 102656000.0 (up 9.7% YoY), and the FY2025 full-year result was 81130000.0, up 33.88% from the prior year.
- Income from Continuing Operations declined to 44162000.0 in Q1 2026, from 41209000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 309431000.0 in Q4 2022 to a low of 72625000.0 in Q1 2022.
- A 5-year average of 14254117.65 and a median of 29850000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 890.33% in 2022 and slumped 104.68% in 2023, its largest moves.
- Tracing ZYME's Income from Continuing Operations over 5 years: stood at 309431000.0 in 2022, then tumbled by 104.68% to 14482000.0 in 2023, then plunged by 62.31% to 23506000.0 in 2024, then tumbled by 75.31% to 41209000.0 in 2025, then declined by 7.17% to 44162000.0 in 2026.
- Business Quant data shows ZYME's Income from Continuing Operations at 44162000.0 in Q1 2026, 41209000.0 in Q4 2025, and 19602000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Zymeworks | 1.70 Bn | 1.34 Bn | - | -44.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.16 Mn |
| Dec 31, 2025 | -41.21 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -23.51 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -37.69 Mn |
| Mar 31, 2024 | -31.65 Mn |
| Dec 31, 2023 | -14.48 Mn |
| Sep 30, 2023 | -28.69 Mn |
| Jun 30, 2023 | -51.15 Mn |
| Mar 31, 2023 | -24.35 Mn |
| Dec 31, 2022 | 309.43 Mn |
| Sep 30, 2022 | -47.85 Mn |
| Jun 30, 2022 | -64.62 Mn |
| Mar 31, 2022 | -72.63 Mn |
| Dec 31, 2021 | -39.15 Mn |
| Sep 30, 2021 | -60.58 Mn |